Expert Interview
Discussing the recent Phase 2/3 data for Setrusumab currently in development to treat Osteogenesis Imperfecta in Pediatric and Young Adult patients
Ticker(s): MREO, RAREInstitution: Oregon Health & Science University
- Associate Professor of Medicine, Division of Endocrinology, Diabetes and Clinical Nutrition, School of Medicine
- Clinical interest is in Osteoporosis, Parathyroid Disease, Hypophosphatemia, Hypocalcemia, Hypothyroidism, Hyperthyroidism, Transgender Medicine, Male Hypogonadism, Adrenal Gland Disorders, Polycystic Ovarian Syndrome.
- Manages 15-20 patients with Osteogenesis Imperfecta and is familiar with the recent data for Setrusumab
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
